Dodge & Cox Grows Stock Holdings in BioNTech SE Sponsored ADR $BNTX

Dodge & Cox lifted its holdings in BioNTech SE Sponsored ADR (NASDAQ:BNTX) by 315.7% in the 3rd quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The institutional investor owned 3,647,091 shares of the company’s stock after acquiring an additional 2,769,654 shares during the period. Dodge & Cox’s holdings in BioNTech were worth $359,676,000 as of its most recent SEC filing.

Other hedge funds and other institutional investors have also made changes to their positions in the company. Vontobel Holding Ltd. increased its holdings in BioNTech by 17.9% in the 3rd quarter. Vontobel Holding Ltd. now owns 72,096 shares of the company’s stock valued at $7,110,000 after purchasing an additional 10,924 shares in the last quarter. Allianz SE lifted its stake in shares of BioNTech by 635.0% during the second quarter. Allianz SE now owns 5,880 shares of the company’s stock worth $626,000 after purchasing an additional 5,080 shares in the last quarter. Lingohr Asset Management GmbH lifted its stake in shares of BioNTech by 598.4% during the third quarter. Lingohr Asset Management GmbH now owns 47,643 shares of the company’s stock worth $4,699,000 after purchasing an additional 40,821 shares in the last quarter. LBP AM SA boosted its position in shares of BioNTech by 15.7% in the third quarter. LBP AM SA now owns 353,329 shares of the company’s stock worth $34,845,000 after buying an additional 47,859 shares during the period. Finally, Gilder Gagnon Howe & Co. LLC boosted its position in shares of BioNTech by 2.8% in the second quarter. Gilder Gagnon Howe & Co. LLC now owns 667,635 shares of the company’s stock worth $71,083,000 after buying an additional 18,351 shares during the period. Institutional investors and hedge funds own 15.52% of the company’s stock.

Wall Street Analyst Weigh In

Several equities research analysts recently commented on the company. Wall Street Zen downgraded BioNTech from a “hold” rating to a “sell” rating in a report on Saturday. Weiss Ratings reaffirmed a “sell (d-)” rating on shares of BioNTech in a research report on Friday, January 9th. Truist Financial set a $155.00 target price on shares of BioNTech in a research report on Tuesday. Canaccord Genuity Group restated a “buy” rating and issued a $171.00 target price on shares of BioNTech in a research note on Wednesday. Finally, The Goldman Sachs Group reaffirmed a “buy” rating on shares of BioNTech in a report on Wednesday. Twelve equities research analysts have rated the stock with a Buy rating, four have issued a Hold rating and one has issued a Sell rating to the company’s stock. Based on data from MarketBeat.com, BioNTech presently has an average rating of “Moderate Buy” and an average price target of $133.73.

BioNTech Stock Performance

BNTX stock opened at $91.19 on Friday. BioNTech SE Sponsored ADR has a 1 year low of $79.52 and a 1 year high of $124.00. The company has a debt-to-equity ratio of 0.01, a quick ratio of 7.02 and a current ratio of 7.54. The stock has a market capitalization of $20.53 billion, a price-to-earnings ratio of -17.40 and a beta of 1.51. The stock’s fifty day moving average is $106.43 and its two-hundred day moving average is $102.56.

BioNTech Profile

BioNTech SE (NASDAQ: BNTX) is a Germany-based biotechnology company that develops next-generation immunotherapies and vaccines, with a primary focus on messenger RNA (mRNA) technology. Founded in 2008 and headquartered in Mainz, BioNTech advances a platform approach to design and manufacture therapeutics across oncology, infectious diseases and other high unmet-need areas. The company is publicly traded on the NASDAQ exchange and became widely known for its rapid development and global deployment of an mRNA-based COVID-19 vaccine in collaboration with Pfizer.

BioNTech’s core activities include discovery research, clinical development and manufacturing of mRNA-based medicines, personalized cancer immunotherapies, engineered cell therapies, and antibody- and protein-based therapeutics.